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EXPERIMENTAL STUDIES
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Beneficial Effects in Rats With Myocardial Infarction
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OBJECTIVES We investigated the effects of short-term tezosentan treatment on cardiac function,
pulmonary edema and long-term evolution of heart failure (HF) in a rat model of myocardial
infarction (MI).
BACKGROUND Endothelin (ET) may play a major role in the progression from MI to HF. Tezosentan is a
new dual ETA/ETB receptor antagonist.
METHODS Rats were subjected to coronary artery ligation and were treated with either vehicle or
tezosentan (10 mg/kg IV bolus) at 1 h and 24 h after MI. Cardiac hemodynamics and lung
weight were measured at 48 h after MI. Survival was assessed over a five-month period.
RESULTS At 48 h after ligation, vehicle-treated rats developed HF, as evidenced by a marked increase
in left ventricular end-diastolic pressure (LVEDP), reduction in dP/dtmax and mean arterial
pressure (MAP), and development of pulmonary edema. Tezosentan treatment attenuated
the increase in LVEDP and in lung weight and slightly reduced MAP without affecting
dP/dtmax. Infarct size was not modified by tezosentan. Despite the fact that treatment with
tezosentan was stopped after 24 h, the initial tezosentan administration significantly reduced
cardiac hypertrophy (22%) and decreased mortality by 51% at five months (50% survival vs.
19% survival in vehicle-treated rats, p  0.001).
CONCLUSIONS Tezosentan administered during the first day after MI in rats, in addition to improving
acutely hemodynamic conditions, markedly increases long-term survival. This increase is
associated with a decrease of pulmonary edema and prevention of cardiac hypertrophy.
Tezosentan could be a safe and useful therapeutic agent in the prevention and treatment of
ischemic HF. (J Am Coll Cardiol 2002;39:142–7) © 2002 by the American College of
Cardiology
Endothelin (ET) plays a major role in the pathophysiology
of chronic heart failure (CHF) (1,2). Significant elevations
of plasma big ET-1 and ET-1 levels are observed in animal
models and patients with CHF, and these elevations are
strongly related to survival in patients with CHF (1–8). The
transition from left ventricular (LV) dysfunction to overt
heart failure (HF) can be prevented by long-term treatment
with the dual ET receptor antagonist bosentan. Long-term
treatment with bosentan has a beneficial effect on hemody-
namics in animal models and in patients with CHF (3–5,9–
12). Long-term treatment with ET receptor antagonists
greatly improves the survival of rats with CHF (9,10).
Endothelin may play also an important role in the
consequence of myocardial infarction (MI). Endothelin-1
levels are markedly elevated in patients with MI or unstable
angina (13), and plasma concentrations of ET-1 are the best
predictive factor of one-year mortality after MI (8). Finally,
long-term treatment with bosentan prevents the develop-
ment of cardiac hypertrophy and ventricular dilation when
started early (14,15) or late (9) after MI induction in rats.
However, little is known on the effects of ET receptor
antagonists in the acute phase (first 2 days) after MI and
whether a short-term (2 days) ET receptor blockade could
have a long-lasting beneficial effect.
Tezosentan is a new, potent dual ETA/ETB receptor
antagonist designed for parenteral use (16). It is currently in
advanced clinical development for the treatment of acute
HF. The present study was designed to investigate in a rat
model whether acute ET receptor blockade with tezosentan
has short-term and long-term beneficial effects after MI.
For this purpose, the effects of tezosentan on cardiac
function and pulmonary edema were evaluated two days
after MI. Then survival was evaluated during the five
months after MI while treatment with tezosentan was given
only for 24 h after MI.
The present study shows that ET receptor blockade can
have long-lasting beneficial effects after MI, even when
given only during the first day after MI.
MATERIALS AND METHODS
Studies were performed on 218 male normotensive Wistar
rats weighing 200 to 270 g. All rats were housed in
From *Actelion Ltd., Allschwil, Switzerland; and the †Department of Pharmacol-
ogy, Shanghai Institute of Materia Medica, Shanghai, China. This work was
supported by Actelion Ltd., Allschwil, Switzerland.
Manuscript received February 22, 2001; revised manuscript received September 10,
2001, accepted September 10, 2001.
Journal of the American College of Cardiology Vol. 39, No. 1, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01692-8
climate-controlled conditions with a 12-h light/dark cycle
and free access to normal rat chow and drinking water. The
animals were handled according to the “Position of the
American Heart Association on Research Animal Use”
adopted November 11, 1984, by the American Heart
Association.
Induction of MI. Myocardial infarction was produced
using a previously described method (9). In brief, rats were
anesthetized with a mixture of ketamine-Rompun (50 mg/kg
to 5 mg/kg, IP). The trachea was intubated (20G cannula),
and the lungs were ventilated with a rodent ventilator
(Model 7025 Rodent Ventilator, Hugo Sachs Elektronik,
March-Hugstetten, Germany) at a rate of 60 cycles/min and
a tidal volume of 1 ml/100 g body weight (BW). A left
thoracotomy was performed, and the left coronary artery
was ligated approximately 2 mm from its origin with a 6-0
silk suture, between the pulmonary artery outflow tract and
left atrium. The sham-operated rats were subjected to the
same procedure, except that the coronary artery was not
ligated. The chest was then closed in three layers (ribs,
muscles and skin). The remaining air was aspirated from the
thorax, allowing the rats to resume spontaneous respiration.
The rats were allowed to recover from anesthesia and
returned to their cages.
Evaluation of the effects of tezosentan. Tezosentan (Ro
61-0612, 10 mg/kg, IV) or vehicle (saline, 1 ml/kg, IV) was
administered at 1 h and 24 h after MI. Sham-operated rats
were treated with saline at the same time points. Different
sets of experiments were then performed.
CARDIAC HEMODYNAMICS AT 48 H. Cardiac hemodynamics
was assessed at 48 h after coronary ligation or sham
operation. Rats subjected to coronary artery ligation were
treated with tezosentan (n  11) or vehicle (n  10). The
third group consisted of sham-operated rats (n  7). At
48 h after MI, rats were anesthetized with sodium hexobar-
bital (Inactin, 100 mg/kg, IP). Body temperature was
maintained at 36 to 38°C, and a tracheotomy was per-
formed. A 2F high-fidelity catheter (SPR-249, Millar
Instruments Inc., Houston, Texas) was inserted via the right
carotid artery into the left ventricle (LV) for recording of
LV pressures, heart rate (HR) and maximal rate of rise of
LV pressure (dP/dtmax). A polyethylene catheter was placed
into the left femoral artery and connected to a pressure
transducer (MLT1050 precision BP transducer, AD Instru-
ments, Hastings, United Kingdom) for continuous blood
pressure measurement. The data acquisition system con-
sisted of a PowerLab (ML780 PowerLab/8s and ML118
QUAD amplifiers, AD Instruments, Hastings, United
Kingdom) connected to a HP Pavilion 8565C computer
with Chart software (version 3.4, AD Instruments, Hast-
ings, United Kingdom).
After surgery and a stabilization period of 15 min, mean
arterial pressure (MAP), LV systolic pressure, LV end-
diastolic pressure (LVEDP), HR and dP/dtmax were re-
corded for 30 min. Calibration of the Millar catheter was
verified before and after each measurement.
LUNG WEIGHT AND MORPHOLOGY. In another set of ex-
periments, lung weight was determined in the same three
groups of animals: MI rats treated with tezosentan (n 23)
or vehicle (n  24) and sham-operated rats (n  10). The
rats were sacrificed 48 h after coronary artery ligation or
sham operation, and the lungs were removed and weighed.
The lungs were fixed in 10% buffered formalin and embed-
ded in paraffin. Sections of 4 m thickness were stained
with hematoxillin and eosin and examined under light
microscopy. In this set of experiments, morphometric eval-
uation of the LV was performed to determine the infarct
size, as described below.
LONG-TERM SURVIVAL STUDY. In a third study, infarct size,
cardiac weight and survival rate were analyzed after MI and
treatment with tezosentan or saline. Three groups of rats,
tezosentan-treated rats (n  54), vehicle-treated rats (n 
59) and sham-operated rats (n  20), were studied over
150 days. Animals were inspected for death twice a day on
weekdays and daily on weekends and holidays. For each rat
dying beyond seven days after MI and during the five-
month period, BW was measured, and the heart was
dissected and weighed. The right ventricle (RV) and LV
plus septum (LVS) were separated and weighed. Mor-
phometric evaluation of the LV was performed to determine
the infarct size. The animals surviving at 150 days after
coronary ligation were sacrificed and similar measurements
were performed. Body and heart weights (total heart, RV,
LVS) were measured, and the LV was processed for
morphometric evaluation of infarct size.
MORPHOMETRIC EVALUATION OF INFARCT SIZE. After
dissection, the LVS was fixed in 10% buffered formalin
for morphometric evaluation of infarct size. The LV was cut
from apex to base into four transverse segments. The middle
two segments, representing the bulk of the LV, were
embedded in paraffin, sectioned and stained. Four slices
from these segments were projected onto a screen for
morphometry. The entire length of the endocardial circum-
ference and the segment of the endocardial circumference
represented by the infarcted segment of each of the four
Abbreviations and Acronyms
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CHF  chronic heart failure
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HR  heart rate
LV  left ventricle
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143JACC Vol. 39, No. 1, 2002 Clozel et al.
January 2, 2002:142–7 Dual ET Receptor Blockade and Myocardial Infarction
slices of the LV were measured. The entire length of the
epicardial circumference and the segment of the epicardial
circumference represented by the infarcted segment of each
of the four slices of the LV were measured. These were then
averaged for each of the four slices. The fraction of the
infarcted ventricle was calculated as the average of the four
slices expressed as a percent of the length of circumference.
Statistical analysis. All data are presented as mean 
SEM. Statistical analysis was performed by analysis of
variance using Statistica (StatSoft) for assessing the differ-
ences in variables between groups. Significant differences
were then subjected to post-hoc analysis using the Student-
Newman-Keuls procedure. Statistical significance was de-
fined as p  0.05. Survival analysis was performed by a
log-rank test using SAS for assessing the difference between
the two groups. Statistical significance was defined by a p
value 0.05.
RESULTS
Cardiac hemodynamics at 48 h. Compared with sham-
operated rats, vehicle-treated MI rats developed HF, which
was characterized by a highly significant increase in
LVEDP with mean values of 19.4  1.5 mm Hg versus
2.8  0.6 mm Hg (p  0.001) and by significant decreases
in the maximal rate of rise of LV pressure (LV dP/dtmax)
and MAP (Table 1). Tezosentan administered at 1 h and
24 h after MI significantly reduced LVEDP by 55%
compared with vehicle-treated MI rats (p  0.001). Mean
arterial pressure tended to be lower in tezosentan-treated
compared with vehicle-treated rats. There was no signifi-
cant effect on LV dP/dtmax (Table 1).
Lung weight and morphology. Baseline values of BW
were similar in all groups before surgery. At 48 h after MI,
vehicle-treated rats had a significantly lower BW compared
with sham-operated rats. Tezosentan significantly reduced
the BW loss compared with vehicle-treated rats. Lung
weight and lung weight/BW increased compared with
sham-operated animals, suggesting that pulmonary edema
occurred in the acute phase following coronary artery
ligation. Treatment with tezosentan at 1 h and 24 h
attenuated the increase in lung weight and lung weight/BW
at 48 h compared with vehicle-treated rats (Fig. 1 and Fig. 2).
In this set of experiments, tezosentan had no effect on
infarct size (38  2% vs. 41  1% in MI  Veh) at 48 h
after MI.
Long-term survival study. At baseline, there was no sig-
nificant difference in BW among the three groups of
animals.
BODY AND HEART WEIGHT. Coronary artery ligation in-
duced a significant decrease in BW (293  10 g vs. 399 
15 g; p  0.001) and marked increases in HW/BW,
RV/BW and LVS/BW compared with sham-operated
animals. Tezosentan significantly prevented decrease in BW
(335  9 g vs. 293  10 g; p  0.01) and the increase in
heart weight and RV weight (Table 2). Heart weight and
LV and RV weight were significantly reduced by tezosentan
when corrected by BW.
INFARCT SIZE. There was no significant difference in infarct
size between tezosentan-treated rats and vehicle-treated rats
(36  1% vs. 38  1%).
SURVIVAL. The mortality during surgery or within 1 h
post-ligation was 1%. During the five-month observation
period, none of the sham-operated rats died. The five-











Sham (n  7) 123  5 439  12 161  7 2.8  0.6 11,066  312
MI  vehicle (n  10) 96  3† 436  7 121  3† 19.4  1.5† 7,379  282†
MI  tezosentan (n  11) 93  2† 432  12 114  3† 8.8  0.7†§ 7,700  243†
†p  0.001 vs. Sham; §p  0.001 vs. MI  vehicle.
dP/dtmax  maximal rate of rise of left ventricular pressure; LVEDP  left ventricular end-diastolic pressure; LVSP  left
ventricular systolic pressure; MAP  mean arterial pressure; MI  myocardial infarction.
Figure 1. Effects of tezosentan on lung weights at 48 h after myocardial
infarction (MI) or sham operation. Tezosentan (10 mg/kg, IV; MI tezo)
or vehicle (saline, 1 ml/kg, IV; MI veh) was injected at 1 h and 24 h after
MI. Sham-operated rats (Sham) received vehicle at the same time points.
Lung weight was measured at 48 h after MI or sham operation. BW 
body weight; **p  0.01; ***p  0.001.
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month survival of vehicle-treated rats with MI was 19%.
Administration of tezosentan at 1 h and 24 h after coronary
artery ligation significantly increased the long-term survival.
The five-month survival of rats treated with tezosentan was
50%, compared with 19% in vehicle-treated rats (p 0.001)
(Fig. 3).
DISCUSSION
This study demonstrates that acute and early administration
of the dual ET receptor antagonist tezosentan prevents the
development of HF and pulmonary edema and significantly
increases the survival rate after MI in rats. The rat model of
MI by coronary artery ligation is well characterized. The
pattern of evolution to overt HF in rats shares many of the
features of CHF in humans. Hemodynamic measurements
at 48 h after coronary artery ligation show depressed cardiac
performance. The increase in lung weight and pulmonary
edema may be due to diastolic dysfunction that was favor-
ably modified by tezosentan. Indeed, tezosentan decreased
LVEDP without having any significant effect on HR and
on cardiac contractility (dP/dtmax). Furthermore, tezosentan
largely prevented significant increase in lung weight and
morphological signs of pulmonary edema in the acute phase
of HF. Finally, tezosentan reduced the development of
cardiac hypertrophy.
Long-term effects of tezosentan. The main finding of this
study is the prevention of long-term mortality after MI by
early and short-term treatment with an ET receptor antag-
onist. Indeed, tezosentan decreased by 51% the five-month
mortality of rats subjected to coronary artery ligation.
Long-term treatment with the dual ET receptor antagonist
bosentan has been shown to improve survival after MI (9).
The effect of bosentan was associated with a decrease in LV
dilation, cardiac hypertrophy and fibrosis, and with a de-
crease in BP and a moderate decrease in HR. In this study,
treatment with bosentan was initiated seven days after MI.
In other studies, bosentan initiated early after MI was also
associated with a reduction in LV dilation (14,15). The
present study confirms the beneficial effect of a dual ET
receptor antagonist given early after MI. Moreover, it is the
first study showing the long-term potential of an acute and
short-term treatment with a dual ET receptor antagonist
after MI.
The mechanism of this increased survival is most likely
related to the prevention of the effects of ET-1.
Endothelin-1 is a potent hypertrophic agent for cardiomy-
ocytes and increases collagen production by cardiac fibro-
blasts (17). The orally active dual ET receptor antagonist
bosentan decreased cardiac hypertrophy in animal models of
hypertension (18,19) and HF (9). Bosentan also reduced
cardiac hypertrophy induced by chronic norepinephrine
infusion (20) and angiotensin II administration (21). In the
present study, tezosentan may have prevented the conse-
quences of the early surge in ET-1 that has been shown to
occur in the present animal model (5,22) and in humans
after MI (8). Because ET-1 plasma levels at three days after
MI are considered the most predictive factor of one-year
mortality in humans (8), the effect of this initial surge of
ET-1 may have long-term consequences. Even though
tezosentan treatment was short-lasting, one can speculate
that it prevented the initial events leading to HF, such as
release of other mediators, coronary and peripheral vasocon-
Figure 2. Light micrographs of the lungs at 48 h after myocardial infarction (MI) or sham operation. Tezosentan (10 mg/kg, IV; MI  tezo) or vehicle
(saline, 1 ml/kg, IV; MI veh) was injected at 1 h and 24 h after MI. Tezosentan largely prevented the lung damage (overt capillary dilation and eosin-like
edematous materials) seen in the vehicle-treated MI rats (MI veh). In sham-operated rats (Sham), no pulmonary capillary dilation or edema was observed
at 48 h after operation. Hematoxillin eosin stain,  100.
Table 2. Effects of Tezosentan on Heart Weights After MI or Sham Operation
BW (g) HW (g) RV (g) LV  S (g) HW/BW (mg/g) RV/BW (mg/g) LV  S/BW (mg/g)
Sham (n  20) 399  15 1.08  0.04 0.18  0.01 0.75  0.03 2.72  0.04 0.45  0.02 1.87  0.03
MI  vehicle (n  51) 293  10† 1.70  0.05† 0.34  0.02† 0.85  0.02* 6.15  0.16† 1.25  0.07† 3.01  0.10†
MI  tezosentan (n  50) 335  9†‡ 1.49  0.05†‡ 0.27  0.01†§ 0.84  0.02* 4.77  0.27†§ 0.89  0.04†§ 2.61  0.09†‡
*p  0.01, †p  0.001 vs. Sham; ‡p  0.01, §p  0.001 MI  vehicle.
BW  body weight; HW  heart weight; RV  right ventricular weight; LV  S  left ventricular plus septum weight.
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striction and LV dysfunction. Accordingly, ET receptor
blockade was shown to prevent the transition from hyper-
tension to HF (23). Similarly in humans, even though the
increase in ET-1 after MI is of short duration, this ET-1
surge seems to have long-term consequences (13).
Another hypothesis is that tezosentan reduced preload
acutely, resulting in decreased infarct expansion, progressive
wall thickening and chamber dilation.
Effects of tezosentan on pulmonary edema and cardiac
function. In addition to its long-term effects of reducing
cardiac hypertrophy and mortality at five months after MI,
tezosentan exhibited early beneficial effects. The prevention
of pulmonary edema after MI by an ET receptor antagonist
has not yet been described. Endothelin may indeed contrib-
ute to the pathogenesis of pulmonary edema in the acute
phase of HF. Elevated plasma ET-1 levels have been
reported in pulmonary edema (8,24). Endothelin-1 has
pro-inflammatory effects and in particular enhances micro-
vascular permeability (25). It has been shown that ET
promotes lung edema and that an ET receptor antagonist
reduces the lung edema induced by oleic acid or bicuculline
(26–28). Bosentan has been shown to decrease albumin
extravasation and to prevent reduction in plasma volume in
different models of abnormal vascular permeability (29–31).
Tezosentan treatment also significantly prevented hemo-
dynamic alterations after MI. Tezosentan decreased
LVEDP without affecting HR and cardiac contractility
(dP/dtmax). These results are in agreement with earlier
reports showing that ET receptor blockade has a beneficial
effect on hemodynamic parameters in CHF (3–5,9–12).
The beneficial effects of tezosentan on hemodynamics and
pulmonary edema may contribute to the reduced early
mortality and the increased long-term survival seen in this
study.
Effect of tezosentan on infarct size. In contrast, the
beneficial effects of tezosentan on survival are not secondary
to a decrease in infarct size. Indeed, tezosentan had no
significant effect on infarct size. Generally, in models of MI,
ET receptor antagonists act primarily by eliciting coronary
vasodilation when a post-ischemic vasoconstriction is ob-
served during reperfusion (32). In MI models, bosentan was
shown to be cardioprotective in some studies (33–35) but
not others (36,37). Interestingly, in the present study
performed in a permanent ischemia model using coronary
artery ligation, there was no possibility for reperfusion.
Conclusions. The results of the present study are in
agreement with the results of studies performed with early
administration of the dual ETA/ETB receptor antagonist
bosentan. Indeed, long-term bosentan treatment initiated at
3 h (14) or 24 h (15) after MI in rats was associated with a
reduction in LV dilation, ventricular dysfunction and ET-1
expression (14,15). The results obtained with the dual
ETA/ETB receptor antagonists bosentan and tezosentan are
in contrast with those obtained after administration of ETA
selective antagonists early after MI. Indeed, early adminis-
tration of ETA selective antagonists led to aggravation of
LV function and worsening of pulmonary vascular remod-
eling (38–40). Similarly, delayed (seven days) administra-
tion of bosentan led to a marked reduction in mortality at
nine months after MI in rats (9), whereas delayed admin-
istration of an ETA selective antagonist did not lead to
reduction in mortality in two independent reports (39,41).
In a dog model of MI, bosentan-treated, but not BQ-123-
treated, dogs exhibited increased cardiac output, suggesting
that blockade of ETB receptors alone or blockade of both
ETA and ETB receptors is necessary to improve cardiac
function in dogs also (42). Overall, there seems to be a
discrepancy of effects between dual blockade of ETA and
ETB receptors and selective blockade of ETA receptors,
especially when treatment is initiated early after MI.
In conclusion, our results demonstrate that acute and
short-term treatment with the dual ET receptor antagonist
tezosentan markedly increased the long-term survival in a
rat model of MI. This observation suggests that tezosentan
could be a useful therapeutic agent in the prevention of
long-term consequences of MI.
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